114 related articles for article (PubMed ID: 12899664)
1. Does the treatment of primary hyperaldosteronism influence glucose tolerance?
Strauch B; Widimský J; Sindelka G; Skrha J
Physiol Res; 2003; 52(4):503-6. PubMed ID: 12899664
[TBL] [Abstract][Full Text] [Related]
2. Can primary hyperaldosteronism be considered as a specific form of diabetes mellitus?
Widimský J; Strauch B; Sindelka G; Skrha J
Physiol Res; 2001; 50(6):603-7. PubMed ID: 11829322
[TBL] [Abstract][Full Text] [Related]
3. Insulin action in primary hyperaldosteronism before and after surgical or pharmacological treatment.
Sindelka G; Widimský J; Haas T; Prázný M; Hilgertová J; Skrha J
Exp Clin Endocrinol Diabetes; 2000; 108(1):21-5. PubMed ID: 10768828
[TBL] [Abstract][Full Text] [Related]
4. Worsening of lipid metabolism after successful treatment of primary aldosteronism.
Adolf C; Asbach E; Dietz AS; Lang K; Hahner S; Quinkler M; Rump LC; Bidlingmaier M; Treitl M; Ladurner R; Beuschlein F; Reincke M
Endocrine; 2016 Oct; 54(1):198-205. PubMed ID: 27179655
[TBL] [Abstract][Full Text] [Related]
5. [Metabolic Outcomes of Primary Aldosteronism Patients Receiving Adrenalectomy or Spironolactone Treatments].
Xu C; Chen T; Mo D; Zhang T; Zhou F; Tian H; Ren Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Nov; 54(6):1227-1232. PubMed ID: 38162054
[TBL] [Abstract][Full Text] [Related]
6. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas.
Rossi E; Sani C; Perazzoli F; Casoli MC; Negro A; Dotti C
Am J Hypertens; 1995 Sep; 8(9):884-93. PubMed ID: 8541003
[TBL] [Abstract][Full Text] [Related]
7. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study.
Giacchetti G; Ronconi V; Turchi F; Agostinelli L; Mantero F; Rilli S; Boscaro M
J Hypertens; 2007 Jan; 25(1):177-86. PubMed ID: 17143190
[TBL] [Abstract][Full Text] [Related]
8. Long-term results of surgical and conservative treatment of patients with primary aldosteronism.
Horký K; Widimský J; Hradec E; Gregorová I; Hradec M
Exp Clin Endocrinol; 1987 Dec; 90(3):337-46. PubMed ID: 3450533
[TBL] [Abstract][Full Text] [Related]
9. Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study.
Matrozova J; Steichen O; Amar L; Zacharieva S; Jeunemaitre X; Plouin PF
Hypertension; 2009 Apr; 53(4):605-10. PubMed ID: 19221213
[TBL] [Abstract][Full Text] [Related]
10. Changes in Glucose Metabolism after Adrenalectomy or Treatment with a Mineralocorticoid Receptor Antagonist for Primary Aldosteronism.
Lin YF; Peng KY; Chang CH; Hu YH; Wu VC; Chung SD;
Endocrinol Metab (Seoul); 2020 Dec; 35(4):838-846. PubMed ID: 33261310
[TBL] [Abstract][Full Text] [Related]
11. Different pathogenesis of glucose intolerance in two subtypes of primary aldosteronism: Aldosterone-producing adenoma and idiopathic hyperaldosteronism.
Okazaki-Hada M; Moriya A; Nagao M; Oikawa S; Fukuda I; Sugihara H
J Diabetes Investig; 2020 Nov; 11(6):1511-1519. PubMed ID: 32470155
[TBL] [Abstract][Full Text] [Related]
12. [Effect of hypokalemia on glucose metabolism in primary hyperaldosteronism].
Zhang J; Zeng ZP; Zhou YR; Tong AL; Lu L; Song AL; Yan ZL; Chen S; Liang W; Li YX; Qin SW
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Dec; 28(6):745-9. PubMed ID: 17260459
[TBL] [Abstract][Full Text] [Related]
13. Insulin sensitivity in patients with primary aldosteronism: a follow-up study.
Catena C; Lapenna R; Baroselli S; Nadalini E; Colussi G; Novello M; Favret G; Melis A; Cavarape A; Sechi LA
J Clin Endocrinol Metab; 2006 Sep; 91(9):3457-63. PubMed ID: 16822818
[TBL] [Abstract][Full Text] [Related]
14. Serum high-molecular weight adiponectin decreases abruptly after an oral glucose load in subjects with normal glucose tolerance or impaired fasting glucose, but not those with impaired glucose tolerance or diabetes mellitus.
Ozeki N; Hara K; Yatsuka C; Nakano T; Matsumoto S; Suetsugu M; Nakamachi T; Takebayashi K; Inukai T; Haruki K; Aso Y
Metabolism; 2009 Oct; 58(10):1470-6. PubMed ID: 19592051
[TBL] [Abstract][Full Text] [Related]
15. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism.
Catena C; Colussi G; Lapenna R; Nadalini E; Chiuch A; Gianfagna P; Sechi LA
Hypertension; 2007 Nov; 50(5):911-8. PubMed ID: 17893375
[TBL] [Abstract][Full Text] [Related]
16. Diurnal blood pressure pattern in patients with primary aldosteronism.
Zacharieva S; Orbetzova M; Elenkova A; Stoynev A; Yaneva M; Schigarminova R; Kalinov K; Nachev E
J Endocrinol Invest; 2006 Jan; 29(1):26-31. PubMed ID: 16553030
[TBL] [Abstract][Full Text] [Related]
17. The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism.
Somlóová Z; Widimský J; Rosa J; Wichterle D; Strauch B; Petrák O; Zelinka T; Vlková J; Masek M; Dvoráková J; Holaj R
J Hum Hypertens; 2010 Oct; 24(10):625-30. PubMed ID: 20574447
[TBL] [Abstract][Full Text] [Related]
18. Aldosterone excess impairs first phase insulin secretion in primary aldosteronism.
Fischer E; Adolf C; Pallauf A; Then C; Bidlingmaier M; Beuschlein F; Seissler J; Reincke M
J Clin Endocrinol Metab; 2013 Jun; 98(6):2513-20. PubMed ID: 23539730
[TBL] [Abstract][Full Text] [Related]
19. Good blood pressure control on antihypertensives, not only response to spironolactone, predicts improved outcome after adrenalectomy for aldosteronoma.
Zarnegar R; Lee J; Brunaud L; Lindsay S; Kebebew E; Clark OH; Duh QY
Surgery; 2007 Dec; 142(6):921-9; discussion 921-9. PubMed ID: 18063077
[TBL] [Abstract][Full Text] [Related]
20. Primary aldosteronism -- screening, diagnosis and therapy.
Horký K; Gregorová I; Vancura J; Silinková-Málková E; Hradec E
Cor Vasa; 1981; 23(4):265-79. PubMed ID: 7028394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
